

## RENAL CELL CANCER AND SORAFENIB: SKIN TOXICITY AND TREATMENT OUTCOME

**Emilio Bajetta, Giuseppe Procopio, Elena Verzoni, Laura Catena, Sara De Dosso, Marco Platania,  
and Arpine Gevorgyan**

*Unit of Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy*

We describe the case of a young man with refractory renal cell carcinoma who achieved an objective response in a metastatic lesion after biotherapy with the multikinase inhibitor sorafenib and also developed a severe skin reaction. The patient had been previously treated with various combinations of immuno-

chemotherapy without any clinical benefit. We performed a brief review of the literature where similar cases were documented with the use of various anti-EGFR agents. The hypothesis of the correlation of skin toxicity with disease response is not new, but in the absence of any strong evidence remains controversial.

**Key words:** multikinase inhibitor, rash, renal cancer, sorafenib.